Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
about
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaRole of the tumor microenvironment in mature B-cell lymphoid malignanciesLymphoma Immunotherapy: Current StatusIbrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionManagement of mantle cell lymphoma in the elderly patientMantle cell lymphoma: observation to transplantationLenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsNovel CD20 monoclonal antibodies for lymphoma therapySingle-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersA retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphomaOral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 studyLenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesMantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K AxisDegrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.A review of the history, properties, and use of the immunomodulatory compound lenalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.Targeted therapy in lymphoma.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraNew strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesA dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaNovel therapeutics for aggressive non-Hodgkin's lymphoma.Molecular targeted approaches in mantle cell lymphoma.HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaExpanding role of lenalidomide in hematologic malignanciesUpdated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.Ongoing trials in low-grade lymphomaPharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
P2860
Q26738937-1CD5AD6B-1E44-4DF9-9857-8F3EE3A0C49EQ26748775-F3565228-5C6E-46B9-A1CD-D2E6636D42EEQ26782902-DFD21EB1-DFC3-43F9-A039-688C5926F7BEQ26783430-A1E7C70D-3E9C-47AC-A2CE-73B39FA97E34Q26999395-6DB44508-5878-43A1-82A6-6398BFC9146EQ28256317-65E8383D-27A9-4424-8C3F-A95370725488Q28303091-B103ACC0-7748-422C-8CCB-D1B69B1DA346Q28390112-922FB687-7E01-4FB0-97D3-96B07086C8FDQ30358639-EF41605D-9A19-4B44-B2B7-CDE72D0B4A75Q33388648-85313FBB-6A95-4D13-B549-075B56221A17Q33393623-760B0B86-1D4B-4234-88F4-91345EC50BD5Q33394623-355EB554-A0AE-4F09-B04F-068DBB9CA877Q33396036-E519FE60-0D8C-48DB-977C-871F872B07BDQ33398019-2F60E396-89EA-49C0-B478-217EA3377E9BQ33398818-38718CA1-48E1-4903-B649-35BF10A9F934Q33405103-8A14FBC6-662C-4185-BCE7-CB7A2EAEC1B2Q33408772-A2782682-C6A9-4946-8373-56928D2D8C8AQ33410282-D09C9B7A-9519-41C1-A1DB-8084BBA4FC0BQ33416695-A453D959-9269-4D2F-BB7A-B80FD97B422EQ33418964-D3CE6CE7-C546-472E-8758-2454C43C3AC4Q33423873-9659EEAF-5771-4F05-8461-67FB4C804311Q33586239-C7A1DDDF-5481-4431-A1B2-16D12AE93C56Q33817800-211C1FA1-21FC-416F-A811-49EFF93BD7A6Q33832937-30327A90-465B-4D07-8365-4E92DF8B52F1Q34129360-63B7C729-F9AE-4DB2-A1EC-5567FC401EB3Q34173071-ABEAEE21-28C9-4F24-8F9C-49DE839837DBQ34220013-BB789A04-019E-4DF2-A5D6-B3368463FE3FQ34253548-7CA5EA28-1082-49D6-A463-62458892F659Q34365673-B80D6F70-A624-4AA9-9948-FE04975BD486Q34413686-CCA3ADBB-3795-47F5-B672-E548313CD049Q34568868-1DBBB1C9-EC15-48D7-BAFD-20074EEAD47BQ34683488-7175A092-CA29-48B3-837E-3468DCDCA633Q35033519-3FF7235E-EC47-4C81-A292-8940635B9FA6Q35111768-976F1E08-0E28-4C9B-A89F-46C9AEBC1BE9Q35127368-9255B4E3-EA4E-4950-9E20-DEE703FF94A6Q35483623-E17D65F4-6FC9-4CC8-AC5D-D80C86F0FFECQ35592305-232C35B7-7A92-44FF-9D27-35BA84A3600EQ35629679-8DBDEF38-2FBC-4D30-9CC5-94BE1302E713Q35715996-D35B1D32-2C4D-458F-A302-B3E3DB0CB09CQ35777792-D8D69A69-F2A3-486D-A6EA-49B7A54DE4CC
P2860
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.
@ast
Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.
@en
type
label
Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.
@ast
Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.
@en
prefLabel
Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.
@ast
Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.
@en
P2093
P1476
Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.
@en
P2093
Annette Ervin-Haynes
Dennis Pietronigro
Glen Justice
Izidore S Lossos
Jerome B Zeldis
Joseph M Tuscano
Kenichi Takeshita
Kenton Wride
Kyle McBride
Peter H Wiernik
P304
P356
10.1111/J.1365-2141.2009.07626.X
P407
P50
P577
2009-02-24T00:00:00Z